Dr. Jennifer M. Levine
Claim this profileNYP/Weill Cornell Medical Center
Expert in Brain Tumor
Expert in Cancer
14 reported clinical trials
32 drugs studied
Area of expertise
1Brain Tumor
Global LeaderStage I
Stage II
MTOR positive
2Cancer
Global LeaderStage I
Stage II
MTOR positive
Affiliated Hospitals
Clinical Trials Jennifer M. Levine is currently running
CPX-351 + Gilteritinib
for Acute Myeloid Leukemia
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone.
Recruiting2 awards Phase 3
Health Information Collection
for Childhood Cancer
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Recruiting1 award N/A10 criteria
More about Jennifer M. Levine
Clinical Trial Related8 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Jennifer M. Levine has experience with
- Larotrectinib
- Palbociclib
- Erdafitinib
- Selpercatinib
- Tipifarnib
- Vemurafenib
Breakdown of trials Jennifer M. Levine has run
Brain Tumor
Cancer
Langerhans Cell Histiocytosis
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jennifer M. Levine specialize in?
Jennifer M. Levine focuses on Brain Tumor and Cancer. In particular, much of their work with Brain Tumor has involved Stage I patients, or patients who are Stage II.
Is Jennifer M. Levine currently recruiting for clinical trials?
Yes, Jennifer M. Levine is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Jennifer M. Levine has studied deeply?
Yes, Jennifer M. Levine has studied treatments such as Larotrectinib, Palbociclib, Erdafitinib.
What is the best way to schedule an appointment with Jennifer M. Levine?
Apply for one of the trials that Jennifer M. Levine is conducting.
What is the office address of Jennifer M. Levine?
The office of Jennifer M. Levine is located at: NYP/Weill Cornell Medical Center, New York, New York 10065 United States. This is the address for their practice at the NYP/Weill Cornell Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.